Search Results - "Vila, M Margeli"

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial by Oakman, C., Francis, P.A., Crown, J., Quinaux, E., Buyse, M., De Azambuja, E., Margeli Vila, M., Andersson, M., Nordenskjöld, B., Jakesz, R., Thürlimann, B., Gutiérrez, J., Harvey, V., Punzalan, L., Dell'Orto, P., Larsimont, D., Steinberg, I., Gelber, R.D., Piccart-Gebhart, M., Viale, G., Di Leo, A.

“…In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin…”
Get full text

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study by Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.

“…Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3…”
Get full text

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial by Barnadas, A, Gil, M, González, S, Tusquets, I, Muñoz, M, Arcusa, A, Prieto, L, Margelí-Vila, M, Moreno, A

“…To assess the efficacy of exemestane as neoadjuvant treatment, 55 postmenopausal women (mean age: 76 years; range: 66–86) with oestrogen-positive…”
Get full text

120P Prognostic significance of SAMHD1 expression in breast cancer by Margeli Vila, M., Felip, E., Gutierrez, L., Riveira, E., Quiroga, V., Romeo, M., Cirauqui, B., Teruel, I., Pous, A., Ferrando, A., Martinez-Cardús, A., Ballana, E.

Get full text

268P Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions by Pla, H., Recalde Penabad, S., Vinas Villaro, G., Margeli Vila, M., Obadia Gil, V.L., Cirauqui Cirauqui, B., Del Barco Berron, S., Gil, M.J., Quiroga Garcia, V., Teruel-Garcia, I., Pernas Simon, S., Stradella, A., Esteve Gomez, A.M., Felip, E.

Get full text

88P Genetic platforms in hormone receptor (HR)+ early breast cancer (eBC): Could logistic regression models be used instead? by Lopez Paradis, A., Pous, A., Notario Rincon, L., Sebastià, G. Cerdà, Sant Albors, M., Bergamino, M.A., Ferrando Diez, A., Teruel-Garcia, I., Romeo Marin, M., Quiroga Garcia, V., Cirauqui Cirauqui, B., Margeli Vila, M., Felip Falgas, E.

Get full text

387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer by Pascual, T., Solis, E. Segui, Olivera-Salguero, R., Cejalvo, J.M., Oliveira, M., Ortega, P. Tolosa, Losada, M.J. Vidal, Malumbres, M., Gavilá-Gregori, J., Manich, C. Saura, Simon, S. Pernas, Vila, M. Margeli, Ciruelos, E.M., Galve-Calvo, E., Galván, P., Sanfeliu Torres, E., Olmos, R., Forns, M., Fernandez Tejerina, A. Casas, Prat, A.

Get full text

301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1 by Lu, Y-S., Chiu, J., Airoldi, M., Vila, M. Margeli, Lorenzo, J. Ponce, Ghaznawi, F., Gaudenzi, F., Ridolfi, A., Lorenzo, I., Borrego, M. Ruiz

Get full text

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer by Oliveira, M., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa Ortega, P., Martinez Saez, O., Salvador Bofill, F.J., Cruz Jurado, J., Luna Barrera, A.M., Arumi de Dios, M.A., Vidal Losada, M.J., Guerra, J.A., Pernas Simon, S., Villacampa Javierre, G., Gonzalez-farre, B., Sanfeliu Torres, E., Santhanagopal, A., Falato, C., Ferrero Cafiero, J.M., Pascual, T., Prat, A.

Get full text

285PSecond primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M, Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, García, I Teruel, Vila, M Margeli

“…Abstract Background The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general…”
Get full text

Second primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M., Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, Te García, I ruel, Vila, M Margeli

Get full text

285P - Second primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M., Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, Te García, I ruel, Vila, M Margeli

“…The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general population. Tamoxifen,…”
Get full text

10P Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i) by Martinez Saez, O., Felip Falgas, E., Cappelletti, M., Tolosa, P., Brasó-Maristany, F., Sanfeliu Torres, E., Pascual, T., Chic, N., Vidal, M., Adamo, B., Munoz, M., Faull, I., Odegaard, J., Patel, G., McEwen, R., Carroll, D., Ciruelos, E.M., Generali, D.G., Margeli Vila, M., Prat, A.

Get full text

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial by Prat, A., Falato, C., Pare Brunet, L., Martinez Saez, O., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa, P., Salvador Bofill, F.J., Cruz Jurado, J., Gonzalez-Farre, B., Sanfeliu Torres, E., Ciruelos, E.M., Espinosa-Bravo, M., Izarzugaza Peron, Y., Pernas Simon, S., Esker, S., Fan, P-D., Ferrero Cafiero, J.M., Pascual, T., Oliveira, M.

Get full text

2O ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis by Pascual, T., Oliveira, M., Ciruelos, E.M., Bellet Ezquerra, M., Saura, C., Gavila Gregori, J., Pernas Simon, S., Muñoz, M., Vidal, M.J., Margeli Vila, M., Cejalvo, J.M., González-Farré, B., Espinosa-Bravo, M., Ferrero-Cafiero, J.M., Villagrasa, P., Prat, A.

Get full text

Influence of the 2019-novel coronavirus pandemic on the management of breast cancer by Luna Tomás, M A, Margelí Vila, M, Ríos Gozálvez, C

Get full text

965P Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) by Cirauqui Cirauqui, B., Bernat Peguera, A., Quer Pi-Sunyer, A., Ramírez Serrano, J.L., Domenech Viñolas, M., Teruel García, I., Quiroga García, V., Margeli Vila, M., Chaib, I., Capdevila Riera, L., Ferrando Diez, A., Plaja Salarich, A., Angelats Company, L., España Fernandez, S., Berenguer Peinado, G., Lezcano Rubio, C., Pollan Guisasola, C., Martinez Cardús, A., Rosell Costa, R., Mesia Nin, R.

Get full text

LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC) by Albanell, J., Martinez, M.T.M., Ramos, M., Connor, M.O.', De la Cruz-Merino, L., Santaballa Bertran, A., Martínez-Jáñez, N., Moreno, F., Fernández Pérez, I., Alarcon Company, J., Virizuela Echaburu, J.A., De la Haba Rodríguez, J., Sánchez-Rovira, P., González-Cortijo, L., Margeli Vila, M., Sánchez Munoz, A., Garau Llinas, I., Casas, M., Bezares Montes, S., Rojo Todo, F.

Get full text

143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study by Kahan, Z., Gil-Gil, M., Ruiz-Borrego, M., Carrasco, E.M., Ciruelos, E.M., Muñoz, M., Bermejo De Las Heras, B., Margeli Vila, M., Anton, A., Casas, M., Calvo, L., de la Haba, J., Ramos, M., Álvarez-López, I., Gal-Yam, E., Gautier, E., Corsaro, M., Rodrigálvarez, G., Zielinski, C., Martin Jimenez, M.

Get full text

37P Enhanced tumor-immunity drives resistance to CDK4/6 inhibitors in advanced breast cancer by Bergamino, M.A., Falgas, E. Felip, Checkhun, S., Diez, A. Ferrando, Cirauqui, B. Cirauqui, Teruel-Garcia, I., Marin, M. Romeo, Quiroga, V., Pous, A., Paradis, A. Lopez, Riveira-Muñoz, E., Ballana, E., Vila, M. Margeli

Get full text